Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response (AFR22)
Multicentric Phase II Study to Evaluate Feasibility and Efficacy of Association of Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response After One Year of Imatinib Mesylate Monotherapy
Sponsor: Institut Bergonié
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Institut Bergonié
Other Myeloid Leukemia, Chronic trials with similar outcome
Listed as NCT00210119, this PHASE2 trial focuses on Myeloid Leukemia, Chronic and remains terminated or withdrawn. Sponsored by Institut Bergonié, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Jul 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut Bergonié
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .